ALPMF (Astellas Pharma) Total Long-Term Assets: $13,518 Mil (As of Mar. 2026)


ALPMF Astellas Pharma Inc ALPMF
77 GF Score
Price $12.85
GF Value $14.20
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Total Long-Term Assets?

Astellas Pharma ALPMF -9.82% 77 Total Long-Term Assets is $13,518 Mil as of Mar. 2026. GuruFocus rates ALPMF with a GF Score™ of 77/100 and a GF Value™ of $14.20 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Astellas Pharma's Total Long-Term Assets for the quarter that ended in Mar. 2026 was $13,518 Mil.

Astellas Pharma Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Total Long-Term Assets Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11,882.88 10,523.11 15,851.66 14,344.76 13,518.29

Astellas Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14,344.76 14,136.58 14,076.91 13,870.64 13,518.29
ALPMF
77GF Score
Astellas Pharma Inc ALPMF
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $13,518 Mil mean?
Astellas Pharma (ALPMF) has a Total Long-Term Assets of $13,518 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Total Long-Term Assets too high?
Astellas Pharma's current Total Long-Term Assets is $13,518 Mil. Overall, Astellas Pharma has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Total Long-Term Assets compare to LLY and JNJ?
Astellas Pharma's Total Long-Term Assets of $13,518 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Total Long-Term Assets is $13,518 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $14.20, compared to a current price of $12.85 — trading 9.5% below its estimated fair value. The current Total Long-Term Assets is $13,518 Mil. Astellas Pharma's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Total Long-Term Assets is $13,518 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (ALPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of $12.85 is trading 9.5% below its estimated GF Value™ of $14.20. GuruFocus considers Astellas Pharma to be Modestly Undervalued.

Key valuation signals for ALPMF:

  • Total Long-Term Assets: $13,518 Mil
  • GF Value™: $14.20 vs. price of $12.85 (9.5% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
77GF Score

Get the complete analysis for ALPMF

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.85
Price
$14.20
GF Value